VBI Vaccines’ Promising Glioblastoma Treatment Data

VBI Vaccines (VBIV) has released an update.

VBI Vaccines Inc. is presenting new Phase 2b interim data on their cancer vaccine, VBI-1901, targeting recurrent glioblastoma, at the 2024 ASCO Annual Meeting. The data includes promising results from initial patients and additional findings from newly added participants. The study, which aims to show significant improvements in overall survival, is a key factor for FDA approval of new oncology treatments.

For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.